Lv5
1070 积分 2024-10-25 加入
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment
2个月前
已完结
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
3个月前
已完结
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment
3个月前
已完结
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
3个月前
已完结
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
3个月前
已完结
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma
4个月前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease
4个月前
已完结
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
4个月前
已完结
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
4个月前
已完结
Resmetirom for NASH: balancing promise and prudence
5个月前
已完结
皖公网安备34019202002308
